Skip to main content
Fig. 4 | BMC Ophthalmology

Fig. 4

From: Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study

Fig. 4

Mean change in CSFT from baseline up to Month 12. For post-baseline visits, baseline is defined as the last available non-missing value collected just prior to the start of treatment. For Group I, error bars are shown in the positive direction and for Group II, error bars are shown in the negative direction. CSFT, central subfield thickness; n, number of patients with Month 12 BCVA data; OCT, optical coherence tomography; VA, visual acuity

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us